Zentiva

PreclinicalSmall molecule

Zentiva is one of 31 small molecule programs targeting Attention Deficit Hyperactivity Disorder. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Attention Deficit Hyperactivity DisorderActive, not recruiting

Attention Deficit Hyperactivity DisorderPreclinical

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Attention Deficit Hyperactivity Disorder

#DrugCompanyPhaseTrials

Ritalin

Novartis

Approved

27 2

Strattera

MMap77

Approved

26 3

Vyvanse

Takeda

Approved

2 4

Revia

Teva

Approved

2 5

Nicorette

Pfizer

Approved

1 6

Intuniv

PPromius Pharma, LLC

Approved

6 7

Rocaltrol

Brintellix

Buspar

Northera

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

A Study to Test Different Ways to Measure the Effect of Atomoxetine on Impulsive Behavior in Young Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·N/A·NCT05278104·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zentiva. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zentiva compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zentiva. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boehringer Ingelheim company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Boehringer Ingelheim

Zentiva

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Attention Deficit Hyperactivity Disorder1 trial

References

Drug Info

Quick Facts

Related News